TGFB1 and pulmonary arterial hypertension: Given the prominent roles of TGF-β in fibrotic diseases and cancer, diverse therapeutic approaches for inhibiting TGF-β-mediated signaling are being explored preclinically and clinically for those indications (152, 153) and could potentially be useful for treating PAH.